Drugs /

pemetrexed

Back to Drugs List
Associated Diseases

Overview

Generic Name(s):
pemetrexed
Trade Name(s):
Alimta
NCI Definition [1]:
A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for pemetrexed

Pemetrexed has been investigated in 149 clinical trials, of which 130 are open and 19 are closed. Of the trials investigating pemetrexed, 1 is early phase 1 (0 open), 37 are phase 1 (26 open), 14 are phase 1/phase 2 (12 open), 57 are phase 2 (55 open), 2 are phase 2/phase 3 (2 open), 36 are phase 3 (34 open), and 2 are phase 4 (1 open).

EGFR L858R, EGFR Exon 19 Deletion, and EGFR L861Q are the most frequent biomarker inclusion criteria for pemetrexed clinical trials.

Non-small cell lung carcinoma, non-squamous non-small cell lung carcinoma, and malignant pleural mesothelioma are the most common diseases being investigated in pemetrexed clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Pemetrexed
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Pemetrexed
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating pemetrexed and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Alimta, pemetrexed, pemetrexed (product), multitargeted antifolate, pemetrexed [chemical/ingredient], pemetrexed (substance), n-(4-(2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid, pemetrexed, l-glutamic acid, n-(4-(2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl), mta, l-glutamic acid, n-(4-(2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-, pemetrexed, l-glutamic acid, n-(4-(2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)
Drug Categories [2]:
Antimetabolites
NCIT ID [1]:
C61614
SNOMED ID [1]:
C-781C4

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.